<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Alkermes</title>
	<atom:link href="http://www.stockbloghub.com/tag/alkermes/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Analyst Maintains Neutral</title>
		<link>http://www.stockbloghub.com/2010/12/20/amln-amylin-pharmaceuticals-analyst-maintains-neutral/60415</link>
		<comments>http://www.stockbloghub.com/2010/12/20/amln-amylin-pharmaceuticals-analyst-maintains-neutral/60415#comments</comments>
		<pubDate>Mon, 20 Dec 2010 22:36:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60415</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). Amylin reported a net loss of $0.31 per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year ago loss of $0.19. Lower revenues resulted in the wider loss. Both Byetta and Symlin revenues declined on a sequential as well as year-over-year basis. Moreover, Amylin faced a huge setback when it failed to gain approval for its lead pipeline candidate, Bydureon, for the second time. Amylin and its partners, Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS), were looking to get Bydureon approved for the treatment of type II diabetes. The latest complete response letter (CRL), which came a few days ahead of the US Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/20/amln-amylin-pharmaceuticals-analyst-maintains-neutral/60415/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes 2010 Second Quarter Revenues Rise &#8211; View Lowered</title>
		<link>http://www.stockbloghub.com/2010/11/24/alks-alkermes-2010-second-quarter-revenues-rise-view-lowered/58507</link>
		<comments>http://www.stockbloghub.com/2010/11/24/alks-alkermes-2010-second-quarter-revenues-rise-view-lowered/58507#comments</comments>
		<pubDate>Thu, 25 Nov 2010 06:59:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58507</guid>
		<description><![CDATA[Alkermes Inc.’s (ALKS) second quarter fiscal 2011 net loss (excluding special items) of 6 cents per share compared unfavorably with the year-ago loss of 5 cents per share. The Zacks Consensus Estimate was a loss of 15 cents per share. The narrower-than-expected loss was attributable to the higher revenues recorded in the quarter. Total revenues for the reported quarter climbed 2% to $49.2 million. The increase was primarily attributable to higher manufacturing, royalty and sales revenues. Revenues for the reported quarter surpassed the Zacks Consensus Estimate of $43 million. We note that Alkermes derives the bulk of its revenue from schizophrenia drug Risperdal Consta. The drug is marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes. Alkermes generated $32.6 million from manufacturing the drug in the reported quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/24/alks-alkermes-2010-second-quarter-revenues-rise-view-lowered/58507/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Reports Wider Loss</title>
		<link>http://www.stockbloghub.com/2010/11/12/amln-amylin-pharmaceuticals-reports-wider-loss/59006</link>
		<comments>http://www.stockbloghub.com/2010/11/12/amln-amylin-pharmaceuticals-reports-wider-loss/59006#comments</comments>
		<pubDate>Fri, 12 Nov 2010 19:44:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59006</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 31 cents per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year-earlier loss of 19 cents. Lower revenues resulted in the wider loss. Revenues of $156.1 million missed the Zacks Consensus Estimate of $159 million. Quarterly Details Total revenues for the quarter declined 19.5% mainly due to lower net product sales. Quarterly revenues consisted of $154.0 million in product sales and $2.1 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $132.4 million in sales of Byetta (exenatide) and $21.6 million in sales of Symlin. Both Byetta and Symlin revenues declined on a sequential ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/12/amln-amylin-pharmaceuticals-reports-wider-loss/59006/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes&#8217; Vivitrol Earns US Food and Drug Administration Clearance</title>
		<link>http://www.stockbloghub.com/2010/10/17/alks-alkermes-vivitrol-earns-us-food-and-drug-administration-clearance/55320</link>
		<comments>http://www.stockbloghub.com/2010/10/17/alks-alkermes-vivitrol-earns-us-food-and-drug-administration-clearance/55320#comments</comments>
		<pubDate>Mon, 18 Oct 2010 03:20:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55320</guid>
		<description><![CDATA[Alkermes Inc. (ALKS) received a boost when the US Food and Drug Administration (FDA) cleared its drug Vivitrol (naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence after opioid detoxification. Opioid dependence refers to a chronic ailment of the brain. The approval of Vivitrol, already available for the treatment of alcohol dependence for which it gained FDA approval in 2006, for the additional indication does not surprise us. Last month, an advisory panel of the FDA had recommended the approval of Vivitrol for treating opioid dependence. The FDA’s Psychopharmacologic Drugs Advisory Committee voted 12-1 in favor of approving Vivitrol for the additional indication. We remind investors that the supplemental New Drug Application (sNDA), seeking to expand Vivitrol’s label, was submitted in April 2010. The application was ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/17/alks-alkermes-vivitrol-earns-us-food-and-drug-administration-clearance/55320/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Earnings Report Shows Revenues Dipped</title>
		<link>http://www.stockbloghub.com/2010/08/10/alks-alkermes-earnings-report-shows-revenues-dipped/47206</link>
		<comments>http://www.stockbloghub.com/2010/08/10/alks-alkermes-earnings-report-shows-revenues-dipped/47206#comments</comments>
		<pubDate>Tue, 10 Aug 2010 17:40:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47206</guid>
		<description><![CDATA[Alkermes Inc.’s (ALKS) first-quarter fiscal 2011 net loss of  14 cents per share compared unfavorably with the year-ago loss of 2 cents per share. The Zacks Consensus Estimate was a loss of 14 cents per share. Quarterly Results Total revenues for the reported quarter declined 11% to $42.3 million. The decline was primarily attributable to lower manufacturing revenues related to the schizophrenia drug Risperdal Consta, which is marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes.  Revenues were also marginally short of the Zacks Consensus Revenue Estimate of $43 million. Manufacturing revenues slipped 7% in the reported quarter to $26.9 million. Manufacturing revenues included $26.3 million from Risperdal Consta. Manufacturing revenues also included $0.6 million related to the manufacture of polymer for Byetta once-weekly (proposed trade name: Bydureon). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/10/alks-alkermes-earnings-report-shows-revenues-dipped/47206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes, Amylin Pharmaceuticals, and Eli Lilly See Encouraging Data on Diabetes Candidate Bydureon</title>
		<link>http://www.stockbloghub.com/2010/06/29/alks-alkermes-amylin-pharmaceuticals-and-eli-lilly-see-encouraging-data-on-diabetes-candidate-bydureon/41922</link>
		<comments>http://www.stockbloghub.com/2010/06/29/alks-alkermes-amylin-pharmaceuticals-and-eli-lilly-see-encouraging-data-on-diabetes-candidate-bydureon/41922#comments</comments>
		<pubDate>Tue, 29 Jun 2010 18:02:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41922</guid>
		<description><![CDATA[Recently Alkermes Inc. (ALKS), Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly &#38; Co. (LLY), the co-developers of type II diabetes candidate Bydureon (exenatide once weekly), presented pooled safety data on the candidate. The companies presented the data at the 70th Annual Scientific Sessions of the American Diabetes Association held in Orlando. The data came from an analysis of the results of three randomized, double-blind studies, which revealed that Bydureon was well tolerated. The studies involved patients treated with either Bydureon (n=541) or other diabetes treatments such as Merck’s (MRK) Januvia, Takeda’s Actos or Sanofi-Aventis’ (SNY) Lantus (n=554). The number of patients opting out of the studies due to serious adverse events was low. Severe hypersensitivity reactions such as serious skin reactions or anaphylaxis were not observed in any of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/29/alks-alkermes-amylin-pharmaceuticals-and-eli-lilly-see-encouraging-data-on-diabetes-candidate-bydureon/41922/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes&#8217; Quarterly Earnings Report Shows Revenue Dip</title>
		<link>http://www.stockbloghub.com/2010/05/17/alks-alkermes-quarterly-earnings-report-shows-revenue-dip/37429</link>
		<comments>http://www.stockbloghub.com/2010/05/17/alks-alkermes-quarterly-earnings-report-shows-revenue-dip/37429#comments</comments>
		<pubDate>Mon, 17 May 2010 22:27:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37429</guid>
		<description><![CDATA[Alkermes Inc. (ALKS) reported a fourth quarter fiscal 2010 net loss of 12 cents per share (excluding special items but including stock-based compensation) compared with a loss of 13 cents per share in the year-ago period; excluding the impact of the termination of  collaboration agreements with Cephalon Inc. (CEPH) and Eli Lilly &#38; Co. (LLY) but including stock-based compensation. The Zacks Consensus Estimate was a loss of 15 cents per share. Quarterly Results Total revenues for the reported quarter declined 12.3% year-over-year to $38.5 million. Manufacturing revenues for the fourth quarter of fiscal 2010 declined 8% year-over-year to $22.6 million. Royalty revenues for the quarter came in at $9.5 million. Research and development revenue under collaborative arrangements dropped to $0.4 million from $1.7 million in the year-ago quarter. The company also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/17/alks-alkermes-quarterly-earnings-report-shows-revenue-dip/37429/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Files New Drug Application For Vivitrol Expansion</title>
		<link>http://www.stockbloghub.com/2010/04/14/alks-alkermes-files-new-drug-application-for-vivitrol-expansion/33706</link>
		<comments>http://www.stockbloghub.com/2010/04/14/alks-alkermes-files-new-drug-application-for-vivitrol-expansion/33706#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:16:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33706</guid>
		<description><![CDATA[Recently Alkermes, Inc. (ALKS) submitted a supplemental New Drug Application (sNDA) for Vivitrol (naltrexone for extended-release injectable suspension) to the US Food and Drug Administration (FDA) for treating opioid dependence. Opioid dependence refers to a chronic ailment of the brain. The affected individual continues to use opioids despite the damage caused by it. Vivitrol, an injectable opioid antagonist administered once-monthly, is already available as an injectable medication for alcohol dependence. The drug received FDA approval in 2006. Vivitrol was initially marketed by Cephalon (CEPH) in the US. However, Cephalon terminated its collaboration with Alkermes ever since December 1, 2008. Alkermes entered into an exclusive agreement with Cilag GmbH International, a subsidiary of Johnson &#38; Johnson (JNJ), to commercialize Vivitrol in Russia and other countries in the Commonwealth Independent States (CIS) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/alks-alkermes-files-new-drug-application-for-vivitrol-expansion/33706/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Drug Pipeline Advances</title>
		<link>http://www.stockbloghub.com/2010/03/19/alks-alkermes-drug-pipeline-advances/31359</link>
		<comments>http://www.stockbloghub.com/2010/03/19/alks-alkermes-drug-pipeline-advances/31359#comments</comments>
		<pubDate>Fri, 19 Mar 2010 22:30:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31359</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) initiated a multidose early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist, which has the potential to block the effects of opioid agonists on gastrointestinal motility, commonly termed as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose early-stage trial is designed to assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37. Approximately 24 healthy volunteers will be studied for a period of one week. The study will see two dose levels of ALKS 37 being tested in sequential cohorts. This study comes after the completion of a previous single dose clinical study in healthy volunteers. In that study ALKS 37 was generally well tolerated and demonstrated low systemic exposure across ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/19/alks-alkermes-drug-pipeline-advances/31359/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals&#8217; Drug Approval Delayed</title>
		<link>http://www.stockbloghub.com/2010/03/16/amln-amylin-pharmaceuticals-drug-approval-delayed/30769</link>
		<comments>http://www.stockbloghub.com/2010/03/16/amln-amylin-pharmaceuticals-drug-approval-delayed/30769#comments</comments>
		<pubDate>Tue, 16 Mar 2010 21:44:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30769</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently issued a complete response letter delaying the approval of Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Co. (LLY) and Alkermes, Inc.’s (ALKS) once weekly formulation of Byetta (exenatide). The companies are seeking to get Byetta once weekly (proposed trade name: Bydureon) approved for the treatment of type II diabetes. Despite the delay, both Amylin and Alkermes shares were up significantly as the agency did not ask the companies to conduct additional clinical or pre-clinical studies. This is encouraging news as additional studies would have delayed approval significantly. We were concerned that safety issues surrounding the use of glucagon-like peptide-1 (GLP-1) molecules like exenatide could have led to the FDA asking for additional safety studies. However, we believe that the final label for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/16/amln-amylin-pharmaceuticals-drug-approval-delayed/30769/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Drug Application Gets New Target Date</title>
		<link>http://www.stockbloghub.com/2010/03/01/alks-alkermes-drug-application-gets-new-target-date/29381</link>
		<comments>http://www.stockbloghub.com/2010/03/01/alks-alkermes-drug-application-gets-new-target-date/29381#comments</comments>
		<pubDate>Mon, 01 Mar 2010 22:57:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29381</guid>
		<description><![CDATA[Recently, the U.S. Food and Drug Administration (FDA) announced that inclement weather has forced the agency to delay the review of the new drug application (NDA) of the type II diabetes candidate, exenatide once-weekly. Exenatide once-weekly is co-developed by Alkermes Inc. (ALKS), Eli Lilly (LLY) and Amylin Pharmaceuticals Inc. (AMLN). The U.S. agency has set March 12, 2010 as the new target date. Originally, the FDA was scheduled to decide on the drug by March 5, 2010. In July 2009, the FDA accepted the NDA for the candidate. The NDA was filed by the three companies in May 2009. Exenatide once-weekly is an injectable formulation of Amylin’s Byetta (exenatide). Byetta is an injection administered twice daily. Exenatide once-weekly has enormous market potential in the $13 billion type II diabetes market. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/01/alks-alkermes-drug-application-gets-new-target-date/29381/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Pipeline Announces Good News</title>
		<link>http://www.stockbloghub.com/2010/02/17/alks-alkermes-pipeline-announces-good-news/28257</link>
		<comments>http://www.stockbloghub.com/2010/02/17/alks-alkermes-pipeline-announces-good-news/28257#comments</comments>
		<pubDate>Wed, 17 Feb 2010 22:40:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28257</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) announced encouraging topline data from an early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist having the potential to block the effects of opioid agonists on gastrointestinal motility, commonly termed as opioid-induced constipation (OIC). Alkermes intends to present full results from the early-stage study at a future medical meeting. The randomized, double-blind, placebo-controlled study evaluated the safety, tolerability and pharmacokinetics of a single oral administration of 5 ascending doses of the candidate, ranging from 1 mg to 100 mg, in 40 healthy volunteers. The data revealed the presence of low systemic exposure at doses up to 100 mg. The finding was consistent with prior preclinical studies which showed that ALKS 37 targets the gastrointestinal tract with limited systemic exposure ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/17/alks-alkermes-pipeline-announces-good-news/28257/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Retains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2010/02/08/alks-alkermes-retains-neutral-recommendation/27398</link>
		<comments>http://www.stockbloghub.com/2010/02/08/alks-alkermes-retains-neutral-recommendation/27398#comments</comments>
		<pubDate>Tue, 09 Feb 2010 03:30:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27398</guid>
		<description><![CDATA[We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. Alkermes has two approved products on the market. Its lead product, Risperdal Consta (or simply Consta), was developed for the treatment of schizophrenia and bipolar disorder. The drug is marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes. Alkermes also receives royalty revenues on Consta sales. Risperdal Consta is the longer-lasting injectable version of Johnson &#38; Johnson&#8217;s schizophrenia drug Risperdal (risperidone). The drug is approved in over 75 countries worldwide and marketed in over 50 countries, but the US is clearly the key ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/08/alks-alkermes-retains-neutral-recommendation/27398/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Reports Lower Third Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/02/05/alks-alkermes-reports-lower-third-quarter-loss/27199</link>
		<comments>http://www.stockbloghub.com/2010/02/05/alks-alkermes-reports-lower-third-quarter-loss/27199#comments</comments>
		<pubDate>Sat, 06 Feb 2010 01:24:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27199</guid>
		<description><![CDATA[Alkermes Inc. (ALKS) reported a third quarter fiscal 2010 net loss of 3 cents per share (excluding items but including stock based compensation) compared with a loss of 9 cents in the year-ago period (excluding the impact of the termination of the collaboration agreements with Cephalon Inc. (CEPH) for Vivitrol but including stock based compensation). Estimate Revisions Trend Two of the 10 analysts covering the stock for the next quarter raised their earnings estimates over the last 30 days while none moved in the opposite direction. This means that majority of them have not revised their estimates for the next quarter, additionally the revision is marginal. Furthermore, two of the 9 analysts covering the stock for the next fiscal year raised their earnings estimates over the last 30 days while ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/alks-alkermes-reports-lower-third-quarter-loss/27199/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Pharma &amp; Biotech Stock Review &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385</link>
		<comments>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26385</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Impresses in Head-to-Head</title>
		<link>http://www.stockbloghub.com/2009/12/16/amln-amylin-pharmaceuticals-impresses-in-head-to-head/23067</link>
		<comments>http://www.stockbloghub.com/2009/12/16/amln-amylin-pharmaceuticals-impresses-in-head-to-head/23067#comments</comments>
		<pubDate>Thu, 17 Dec 2009 05:21:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23067</guid>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (AMLN) recently announced positive results on its once weekly formulation of Byetta (referred to as exenatide once weekly), which is being developed in collaboration with Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS). Amylin presented results from a head-to-head study (DURATION-5) comparing exenatide once weekly with a Byetta injection taken twice daily in patients with type II diabetes. Data showed that after 24 weeks of treatment, patients on exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months (1.6 percentage points versus 0.9 percentage points). While both treatment groups achieved statistically significant weight loss by the end of the study, the average loss was higher in the once-weekly group compared to the Byetta group (5.1 pounds versus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/amln-amylin-pharmaceuticals-impresses-in-head-to-head/23067/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Good News for Alkermes&#8217; Drug Pipeline</title>
		<link>http://www.stockbloghub.com/2009/11/18/alks-good-news-for-alkermes-drug-pipeline-2/20861</link>
		<comments>http://www.stockbloghub.com/2009/11/18/alks-good-news-for-alkermes-drug-pipeline-2/20861#comments</comments>
		<pubDate>Wed, 18 Nov 2009 22:51:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20861</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) announced that its drug Vivitrol, which is indicated for the treatment of alcohol dependence, also helped opioid addicts stay away from drugs. Data from the six-month late-stage trial (n=250) demonstrated that subjects injected with Vivitrol (naltrexone for extended-release injectable suspension) once a month were more likely to pass a urine test compared to recipients of a placebo injection. Furthermore, subjects reported a lower craving for drugs, and half the subjects came clean in at least 90% of their drug tests. The subjects were addicted to opioid drugs including heroin. Before enrolling for the trial, they had to stay away from drugs for at least a week. The most common adverse event affecting patients during the study were inflammation of the nose and throat in addition to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/18/alks-good-news-for-alkermes-drug-pipeline-2/20861/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Moves to Loss but Beats Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/09/alks-alkermes-moves-to-loss-but-beats-consensus-estimates/20142</link>
		<comments>http://www.stockbloghub.com/2009/11/09/alks-alkermes-moves-to-loss-but-beats-consensus-estimates/20142#comments</comments>
		<pubDate>Tue, 10 Nov 2009 00:15:45 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20142</guid>
		<description><![CDATA[Alkermes, Inc. (ALKS) reported a second quarter fiscal 2010 net loss of 5 cents per share, compared with a profit of 2 cents in the year-ago period. The Zacks Consensus Estimate was a loss of 10 cents. Revenues in the quarter increased 1.9 % to $48.2 million from $47.3 million in the year-ago quarter. The increase was driven by manufacturing and royalty revenues from Risperdal Consta. Total manufacturing revenues for the quarter came in at $32.8 million as against $33 million in the year-ago quarter.  Manufacturing revenues for the quarter included $31.9 million related to Risperdal Consta, marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes, compared to $30.7 million for Consta and $2.3 million for Vivitrol for the year-ago quarter. Royalty revenues for the quarter came in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/alks-alkermes-moves-to-loss-but-beats-consensus-estimates/20142/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Big Pharma and Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146</link>
		<comments>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:57:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Good News for Alkermes&#8217; Drug Pipeline</title>
		<link>http://www.stockbloghub.com/2009/10/16/alks-good-news-for-alkermes-drug-pipeline/17689</link>
		<comments>http://www.stockbloghub.com/2009/10/16/alks-good-news-for-alkermes-drug-pipeline/17689#comments</comments>
		<pubDate>Fri, 16 Oct 2009 22:57:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17689</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) announced that its pipeline candidate, ALKS33, for addiction and nervous system disorders, gave positive results in two early stage clinical trials. Results from the two studies, ALK33-003 and ALK33-004, demonstrated that the candidate blocked the effects of an opioid with an action duration that supported once daily dosing. The studies were initiated in May this year. ALK33-003, a randomized, double-blind, placebo-controlled, multi-dose study, evaluated the pharmacokinetics, safety and tolerability of multiple doses of ALKS33 in 30 healthy volunteers. ALK33-004, a randomized, single-blind, placebo-controlled, single-dose study, was designed to examine the ability of ALKS33 to block the effects of an opioid following a single oral dose of ALKS33 in 24 healthy, non-dependent, opioidexperienced subjects. ALKS33, an oral opioid modulator, was generally well-tolerated in both the studies. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/alks-good-news-for-alkermes-drug-pipeline/17689/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Notified Johnson &amp; Johnson Intends to Stop Development of Risperidone</title>
		<link>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717</link>
		<comments>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717#comments</comments>
		<pubDate>Thu, 27 Aug 2009 23:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13717</guid>
		<description><![CDATA[On Wednesday, Alkermes, Inc. (ALKS) disclosed that it has received notification from Johnson &#38; Johnson’s (JNJ) Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International stating that Janssen does not intend to continue with the development of the four-week long-acting injectable formulation of risperidone. A phase I study with the four-week formulation had been initiated in January 2009. Risperidone, which is marketed as Risperdal Consta, is Alkermes’ lead product. Risperdal Consta is the longer-lasting injectable version of Johnson &#38; Johnson&#8217;s schizophrenia drug Risperdal (risperidone). Risperdal Consta uses Alkermes&#8217; proprietary Medisorb technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. The product is approved in more than 85 countries worldwide and is available in 60 countries. Risperdal Consta is superior to the first-generation Risperdal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WYE) Biotech Industry &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310</link>
		<comments>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310#comments</comments>
		<pubDate>Fri, 13 Mar 2009 22:00:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[DCGN]]></category>
		<category><![CDATA[deCODE genetics Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4310</guid>
		<description><![CDATA[OVERVIEW The financial market and the economic landscape in the U.S. have not changed much since the beginning of the year. And we believe the status quo will last for a while at least in 2009. Large biotech companies are doing OK since they have strong balance sheets to weather the current market turmoil and can generate revenue from product sales. Investors in large biotechnology companies worth more than $1 billion have preserved much of their wealth. Smaller biotech companies, particularly those still in development stage, meanwhile, are under severe strain as the global economic slump cuts into sales and their ability to raise fresh cash to fund research. As we expected, the M&#38;A spree has continued in the first three months of this year. Following the acquisition of Wyeth ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

